We have several important news items and updates to share with you: 1.    Noridian Administrative Services (NAS) have recently moved their office to Mountlake Terrace, WA. Below are the new phone numbers for the Education staff, Dr. Hecker and Dr. Whitten. Linda Windley - 425-697-8514 Tammy Ewers - 425-697-8516 Bernice Hecker, MD - 425-697-8542  Dick Whitten, MD - 701 433-3125 Marie Gray - 425-697-8515 Fax number: 425-697-8585 New office address: 6505 216th Street SW, Suite 200 Mountlake Terrace, WA 98043 2.    Last June, legislation passed in Washington requiring the use of tamper proof resistant prescription pads approved by the Board of Pharmacy effective July 1st of this year.    Come July 1, physicians writing prescriptions on non-approved pads will have their prescription refused at the pharmacy. Click Here for an explanation of the new requirement from the Board of Pharmacy Click Here for a sample prescription. If you have questions on this new requirement please contact: Susan Teil Boyer, MS, RPh, FASHP Executive Director Washington State Board of Pharmacy And Clinical Facilities, Health Professions and Facilities Department of Health PO Box 47852 Olympia, Wa 98504-7852 office 360-236-4853 susan.boyer@doh.wa.gov  T                                          If you have questions or comments about the items listed here please email Risë Marie Cleland at: Rise@wsmos.org ASCO Cancer Policy Today

Sanofi-aventis Announces Jevtana Approval Sanofi-aventis is pleased to announce that on June 17, 2010, the US Food and Drug Administration (FDA) approved Jevtana® (cabazitaxel) Injection. In addition, as of July 19, 2010, Jevtana is now commercially available. Product related billing information is provided below: National Drug Codes (NDCs) NDC Assigned:    00024-5824-11        Packaging: Carton of one (1) Jevtana vial & one (1) Diluent vial HCPCS Codes J9999     Not otherwise classified (NOC) antineoplastic drugs C9399    Unclassified drugs or biologicals For more information on Jevtana, please click here for full prescribing information, including boxed WARNING. Updated VELCADE Label Announced On January 4, 2010 Millennium announced that the FDA has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term overall survival data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. the VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM). Click Here to read the press release, Click Here to read the Physician Announcement Letter                       This website brought to you by:   Washington State Medical Oncology Society 113 W. 7th Street Suite 205 Vancouver, Washington 98660 360.258.0443 Phone 360.695.6937 Fax wsmos@comcast.net